Compare IMAX & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IMAX | VERA |
|---|---|---|
| Founded | 1967 | 2016 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.5B |
| IPO Year | 1997 | 2021 |
| Metric | IMAX | VERA |
|---|---|---|
| Price | $39.06 | $31.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 10 |
| Target Price | $44.50 | ★ $81.30 |
| AVG Volume (30 Days) | ★ 1.1M | 1.0M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.25 | N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $410,212,000.00 | N/A |
| Revenue This Year | $9.79 | N/A |
| Revenue Next Year | $7.51 | $472.48 |
| P/E Ratio | $558.57 | ★ N/A |
| Revenue Growth | ★ 16.47 | N/A |
| 52 Week Low | $24.20 | $19.07 |
| 52 Week High | $43.16 | $56.05 |
| Indicator | IMAX | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 56.09 | 38.63 |
| Support Level | $35.37 | $27.19 |
| Resistance Level | $40.56 | $31.92 |
| Average True Range (ATR) | 1.48 | 2.24 |
| MACD | 0.33 | -0.16 |
| Stochastic Oscillator | 75.65 | 18.76 |
Imax Corp is a technology platform for entertainment and events. Through its proprietary software, auditorium architecture, patented intellectual property, and specialized equipment, IMAX offers end-to-end solution to create superior, immersive content experiences for which the IMAX brand is globally renowned. The Company has two reportable segments being Content Solutions and Technology Products and Services. The Company leverages its proprietary technology and engineering in all aspects of its business, which principally consists of the IMAX film remastering and the sale or lease of premium IMAX theater systems.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.